Hyderabad, July 27 Dr Reddy’s Laboratories has launched Bortezomib for Injection, the generic equivalent of Velcade (bortezomib) Injection, in the US market, approved by the US Food and Drug Administration (USFDA).
The Velcade brand and generic had US sales of approximately $1.2 billion in the 12 months ending in May 2022, according to IQVIA Health. Velcade is a trademark of Takeda Pharmaceuticals U.S.A., Inc
Hyderabad-based Dr Reddy’s Bortezomib for Injection, is supplied in a 3.5 mg per 10 ml single-dose vial presentation for subcutaneous or intravenous use, according to a release issued on Wednesday.
Bortezomib for injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and mantle cell lymphoma.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.